GSTP1 and breast carcinoma: Intriguingly, they also demonstrated that GSTP1-containing EVs transferred drug resistance horizontally, and hence proposed their use as negative predictive factors of chemoresistance and clinical outcomes in breast cancer patients treated with anthracycline/taxane-based therapy[141].